ArticleFrontiers in oncology2022
Impact of cryopreservation on CAR T production and clinical response.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Impact of cryopreservation on PBMC-derived CAR-T cell manufacturing outcomes: a systematic review.Frontiers in immunology · 2026Pooled it
- Locally manufacturedHaematologica · 2026Article
- Process Systems Engineering in Precision Medicine: Opportunities in Autologous CAR-T Therapy.Engineering in life sciences · 2026Review
- L-Arginine supplementation improves the survival of virus-specific CD8Immunotherapy advances · 2026Article
- Evaluation of DMSO-free cryopreservation reagent XT-Thrive for establishment of mesenchymal stem cell bank platform.Frontiers in bioengineering and biotechnology · 2026Article
- Article
- From cold chain to ambient: Benefits, risks, and evidence across cell therapy logistics.Molecular therapy. Methods & clinical development · 2025Review
- International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.Blood advances · 2025Article
- Cryopreservation of siRNA-Treated Cells Is Feasible.Nucleic acid therapeutics · 2025Article
- Advancing CAR-T cell therapy: Insights into patient biology, leukapheresis, and cryopreservation.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Glucose-Enhanced Cryopreservation of hCAR-T Cells: Improved Recovery and Reduced Apoptosis.Biomolecules & therapeutics · 2025Article
- Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors.Cancers · 2025Review
- Practice of Cryopreservation of Cellular Starting Materials from the Asia-Pacific Region: An Industrial Perspective.Therapeutic innovation & regulatory science · 2025Review
- Cryopreserved leukapheresis enables scalable and distributed CAR-T manufacturing: a multi-platform comparative study.Scientific reports · 2025Article
- Establishment and evaluation of an immortalized dzo kidney cell line.Scientific reports · 2025Article
- Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects.Frontiers in immunology · 2025Review
- Current Role of CAR-T Therapy in Haematological Care.Advances in experimental medicine and biology · 2025Review
- Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand.Molecular therapy. Oncology · 2024Article
- Advances in manufacturing chimeric antigen receptor immune cell therapies.Seminars in immunopathology · 2024Review
- Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.Experimental hematology & oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptive cell therapy with chimeric antigen receptor (CAR) T cells has become an efficient treatment option for patients with hematological malignancies. FDA approved CAR T products are manufactured in centralized facilities from fresh or frozen leukapheresis and the cryopreserved CAR T infusion product is shipped back to the patient. An increasing number of clinical centers produce CAR T cells on-site, which enables the use of fresh and cryopreserved PBMCs and CAR T cells. Here we determined the effect of cryopreservation on PBMCs and CD19 CAR T cells in a cohort of 118 patients treated with fresh CAR T cells and in several patients head-to-head. Cryopreserved PBMCs, obtained from leukapheresis products, contained less erythrocytes and T cells, but were sufficient to produce CAR T cells for therapy. There was no correlation between the recovery of PBMCs and the transduction efficacy, the number of CAR T cells obtained by the end of the manufacturing process, the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.